ERD 308
CAS: 2320561-35-9
Ref. 3D-VSD56135
| 5mg | To inquire | ||
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Product Information
ERD 308 is a small molecule that inhibits the proteasome-mediated degradation of proteins by inhibiting the ubiquitin-proteasome pathway. ERD 308 binds to the receptor α, which is a component of the ubiquitin ligase complex, and blocks the formation of a ternary complex with ubiquitin and an E1 enzyme. This prevents protein degradation by inhibiting the ubiquitin-proteasome system. ERD 308 has shown anticancer activity in vitro and in vivo, as well as pharmacokinetic properties that are favorable for dosing in humans. The compound has been developed as a potential treatment for breast cancer and other cancers.
Chemical properties
Technical inquiry about: 3D-VSD56135 ERD 308
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
